November 19, 2019 -- MilliporeSigma announced that it is receiving a prestigious R&D 100 Award for its Eshumo CP-FT Resin product, a first-to-market product used in the biopharmaceutical manufacturing industry.
The R&D 100 Awards honor the 100 most innovative and significant technologies introduced in the past year. MilliporeSigma has received 10 R&D 100 Awards in the past seven years. MilliporeSigma representatives will accept the award at the 57th Annual R&D 100 Awards gala in San Francisco, California on December 5.
The cation exchange resin was developed for flow-through removal of aggregates using frontal chromatography. Aggregates are impurities in monoclonal antibody drugs that can reduce efficacy and therefore pose significant risk to patients. They are often difficult to remove in the purification process of drug manufacturing. Eshumo CP-FT resin delivers capacities 10 times higher than traditional bind/elute chromatography. The significant reduction in resin and buffer volume results in a smaller manufacturing footprint as well as lower costs. The resin is part of MilliporeSigma's BioContinuum Polishing Platform.
"This award recognizes our innovation in research and development for a product that helps biomanufacturers bring new therapies to patients faster and more cost effectively," said Udit Batra, CEO, MilliporeSigma. "Congratulations to our extended teams, who live our purpose every day by solving the toughest problems in life science in collaboration with the global scientific community."